Bayer paid Loxo 400m for 2 molecules in 2017 could be a good place to start!
Bayer first partnered with Loxo on the two TRK inhibitors – Vitrakvi (larotrectinib) and LOXO-195 – back in 2017, paying $400 million upfront for the pair with the total value including milestones upwards of $1.5 billion. The deal included an option to take full control of the drugs if Loxo was acquired, and as soon as Lilly’s deal went through Bayer moved swiftly to take full control of them.
https://pharmaphorum.com/news/bayer-control-loxo-duo-lilly-takeover/
Lilly said it will acquire targeted cancer drug maker Loxo Oncology for $8 billion in a deal that gives the Indianapolis Big Pharma the TRK inhibitor Vitrakvi, the first drug approved by the FDA to target tumors according to a genetic abnormality rather than the location of the cancer. The $235-per-share offer is a 68% premium over Loxo's most recent closing price.
